Archive for the ‘avanafil’ tag
Fast-acting PDE-5 inhibitor shows positive results
Agent demonstrates quick onset, short half-life, dose-linked efficacy in phase II study
Avanafil, an investigational, fast-acting phosphodiesterase type-5 inhibitor, has been successful in its first large-scale trial. Joel M. Kaufman, MD, reported at the Sexual Medical Society of North America annual meeting here.
The study, led by Dr. Kaufman, associate clinical professor of urology at the University of Colorado School of Medicine. Denver, was a phase II trial in the sequence of protocols needed to obtain FDA approval for drugs. Plans for a phase III trial, the last step in that sequence, are being made for 2006, according to VIVUS, Inc.. which is developing the drug.